Profile photo of Daniel W. Lee, M.D.
Daniel W. Lee, M.D.
Assistant Clinical Investigator

Center for Cancer Research
National Cancer Institute

Building 10 - Hatfield CRC, Room 1-3750
Bethesda, MD 20892-1104
301-435-6236

Dr. Lee was among the first to develop chimeric antigen receptor (CAR) modified T cell therapy for children and young adults with pre-B cell acute lymphoblastic leukemia and B-cell lymphomas. The clinical trial he leads genetically engineers patient’s own T cells with a CAR targeting the antigen CD19 resulting in remissions in the vast majority of patients with refractory or relapsed disease.

Capitalizing on the success of the CD19-CAR T cell therapy, Dr. Lee’s laboratory now aims to develop other CAR-based therapies for the treatment of medulloblastoma, ependymoma, and other pediatric brain tumors.

Areas of Expertise
1) immunotherapy, 2) chimeric antigen receptor (CAR), 3) pediatric cancer and bone marrow transplantation, 4) acute lymphoblastic leukemia (ALL), 5) medulloblastoma, 6) ependymoma
Link to Clinicaltrials.gov Protocol ID Referral Phone

Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies

NCI-12-C-0112 1-877-624-4878

Survival rates for childhood malignancies have been stagnant, mostly due to a lack of new therapies with novel mechanisms of action. With recent technology advances, adoptive cellular therapy, a type of immunotherapy, is now poised to improve outcomes for both children and adults with cancer. As a fellow, Dr. Lee determined that small doses of T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the pre-B acute lymphoblastic leukemia (ALL) antigen, CD19, could reproducibly cure mice engrafted with ALL. He led efforts to generate GMP-grade anti-CD19 CAR T cells, the first of their kind, produced in the Cell Processing Section, Department of Transfusion Medicine at the NIH. He now serves as the Principal Investigator on a Phase I clinical trial of these CAR T cells for the treatment of children and young adults with B-cell malignancies (NCT01593696). His laboratory efforts are directed at using the experience gained in the clinical trial to inform the next generation of CAR T cells. Through a better understanding of how CARs work in various subsets of T cells, Dr. Lee aims to improve the anti-tumor potential and persistence of these cells after infusion to the patient. For example, T stem cell memory cells (Tscm) are naturally occurring cells possessing a unique collection of properties that, if redirected to tumor antigen via a CAR, may lead to improved outcomes.

Scientific Focus Areas:
Clinical Research, Immunology
Selected Recent Publications
  1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Yuan C, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.
    Lancet. [Epub ahead of print], 2014. [ Journal Article ]
  2. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL.
    Blood. 124: 188-95, 2014. [ Journal Article ]
  3. Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, Wayne A, Sabatino M.
    Cytotherapy. 15: 1406-15, 2013. [ Journal Article ]
  4. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, Fitzgerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
    Blood. 121: 1165-74, 2012. [ Journal Article ]
  5. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA.
    Clin. Cancer Res. 18: 2780-90, 2012. [ Journal Article ]

After completing undergraduate studies at Washington and Lee University, Lexington, Virginia, Dr. Daniel W. 'Trey' Lee received his M.D. from the University of Texas Health Science Center (UTHSC) at Houston in 2003. He then studied as postdoctoral fellow for 2 years in the lab of Seth Corey at MD Anderson Cancer Center. This was followed by his pediatric internship and residency training at UTHSC Houston and Hermann Children's Hospital, which he completed in 2008. He then joined the combined Pediatric Hematology and Oncology Fellowship training program at the National Cancer Institute, Pediatric Oncology Branch (POB) and Johns Hopkins University. Dr. Lee is board certified in General Pediatrics (2010) and Pediatric Hematology and Oncology (2013) and currently serves as an Assistant Clinical Investigator in the POB.

Name Position
Anan Nellan M.D. Clinical Fellow
Christopher Rota Postbaccalaureate Fellow

Summary

Dr. Lee was among the first to develop chimeric antigen receptor (CAR) modified T cell therapy for children and young adults with pre-B cell acute lymphoblastic leukemia and B-cell lymphomas. The clinical trial he leads genetically engineers patient’s own T cells with a CAR targeting the antigen CD19 resulting in remissions in the vast majority of patients with refractory or relapsed disease.

Capitalizing on the success of the CD19-CAR T cell therapy, Dr. Lee’s laboratory now aims to develop other CAR-based therapies for the treatment of medulloblastoma, ependymoma, and other pediatric brain tumors.

Areas of Expertise
1) immunotherapy, 2) chimeric antigen receptor (CAR), 3) pediatric cancer and bone marrow transplantation, 4) acute lymphoblastic leukemia (ALL), 5) medulloblastoma, 6) ependymoma

Clinical Trials

Link to Clinicaltrials.gov Protocol ID Referral Phone

Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies

NCI-12-C-0112 1-877-624-4878

Research

Survival rates for childhood malignancies have been stagnant, mostly due to a lack of new therapies with novel mechanisms of action. With recent technology advances, adoptive cellular therapy, a type of immunotherapy, is now poised to improve outcomes for both children and adults with cancer. As a fellow, Dr. Lee determined that small doses of T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the pre-B acute lymphoblastic leukemia (ALL) antigen, CD19, could reproducibly cure mice engrafted with ALL. He led efforts to generate GMP-grade anti-CD19 CAR T cells, the first of their kind, produced in the Cell Processing Section, Department of Transfusion Medicine at the NIH. He now serves as the Principal Investigator on a Phase I clinical trial of these CAR T cells for the treatment of children and young adults with B-cell malignancies (NCT01593696). His laboratory efforts are directed at using the experience gained in the clinical trial to inform the next generation of CAR T cells. Through a better understanding of how CARs work in various subsets of T cells, Dr. Lee aims to improve the anti-tumor potential and persistence of these cells after infusion to the patient. For example, T stem cell memory cells (Tscm) are naturally occurring cells possessing a unique collection of properties that, if redirected to tumor antigen via a CAR, may lead to improved outcomes.

Scientific Focus Areas:
Clinical Research, Immunology

Publications

Selected Recent Publications
  1. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Yuan C, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.
    Lancet. [Epub ahead of print], 2014. [ Journal Article ]
  2. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL.
    Blood. 124: 188-95, 2014. [ Journal Article ]
  3. Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C, Wayne A, Sabatino M.
    Cytotherapy. 15: 1406-15, 2013. [ Journal Article ]
  4. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, Fitzgerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
    Blood. 121: 1165-74, 2012. [ Journal Article ]
  5. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA.
    Clin. Cancer Res. 18: 2780-90, 2012. [ Journal Article ]

Biography

After completing undergraduate studies at Washington and Lee University, Lexington, Virginia, Dr. Daniel W. 'Trey' Lee received his M.D. from the University of Texas Health Science Center (UTHSC) at Houston in 2003. He then studied as postdoctoral fellow for 2 years in the lab of Seth Corey at MD Anderson Cancer Center. This was followed by his pediatric internship and residency training at UTHSC Houston and Hermann Children's Hospital, which he completed in 2008. He then joined the combined Pediatric Hematology and Oncology Fellowship training program at the National Cancer Institute, Pediatric Oncology Branch (POB) and Johns Hopkins University. Dr. Lee is board certified in General Pediatrics (2010) and Pediatric Hematology and Oncology (2013) and currently serves as an Assistant Clinical Investigator in the POB.

Team

Name Position
Anan Nellan M.D. Clinical Fellow
Christopher Rota Postbaccalaureate Fellow